. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: Clin Colorectal Cancer. 2021 Oct 1;21(2):e62–e75. doi: 10.1016/j.clcc.2021.09.008

Table 3.

Impact of RDI Levels of FOLFOX Chemotherapy on All-Cause Mortality and Cause-Specific Mortality in Low-Risk Stage III Colon Cancer— Multivariable Analysis

RDI	All-Cause Mortality (N = 221)^b			Cause-Specific Mortality (N = 216)
RDI	Low RDI% (RDI<Selected Cutoffs	Adjusted HR^a (95% CI)	P	Adjusted HR^a (95% CI)	P
RDI< 45% vs. RDI≥ 45%	16.3	0.80 (0.24, 2.73)	.72	0.53 (0.06, 4.95)	.58
RDI< 50% vs. RDI≥ 50%	19.9	1.26 (0.47, 3.41)	.65	0.75 (0.16, 3.46)	.71
RD< 55% vs. RDI≥ 55%	22.2	1.24 (0.46, 3.33)	.67	0.74 (0.16, 3.39)	.70
RDI< 60% vs. RDI≥ 60%	27.2	1.08 (0.41, 2.81)	.88	0.40 (0.09, 1.84)	.24
RDI< 65% vs. RDI≥ 65%	31.7	0.96 (0.36, 2.59)	.94	0.79 (0.16, 3.96)	.78
RDI< 70% vs. RDI≥ 70%	40.7	0.80 (0.31, 2.02)	.63	0.93 (0.21, 4.15)	.92

Models adjusted for age, sex, race/ethnicity, insurance coverage, number of positive lymph nodes, tumor grade, Charlson comorbidity index, anatomic subsite, colon cancer classification (colon as the only cancer vs. multiple primary cancers), and delayed chemotherapy.

All variables met the proportional hazards assumption with P values of the correlation coefficient between Schoenfeld residuals and time > .05.